Meeting
2020 ASCO Virtual Scientific Program
A randomized phase II trial of secondary cytoreductive surgery (SCS) +/- carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC).
Presenter
Oliver Zivanovic, MD
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01767675
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6016)
DOI
10.1200/JCO.2020.38.15_suppl.6016
Abstract #
6016
Poster Bd #
187
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2016 ASCO Annual Meeting
Multicenter phase II study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.
Speaker: Kosei Hasegawa, M.D., Ph.D.
Videos & Slides
2024 ASCO Annual Meeting
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
Speaker: Fiona Simpkins, MD
Speaker: Panel Discussion